Skyrizi® (risankizumab-rzaa) is now available as a single-dose 150mg prefilled pen or syringe for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Previously, Skyrizi was available only as two single-dose 75mg prefilled syringes.

The new single-dose 150mg prefilled pen consists of wide grip handles, an inspection window, a green activator button, audible cues to indicate the beginning and end of the administration process, and an indicator to signal when administration is complete. Patients may self-inject Skyrizi after training in subcutaneous injection technique.

In April 2021, the Food and Drug Administration (FDA) approved the supplemental Biologics License Application for the single-dose Skyrizi 150mg injection based on data from 3 clinical trials. Results showed that the single-dose 150mg injection was bioequivalent to two 75mg injections with a consistent efficacy and safety profile. 

Reference

  1. Skyrizi® (risankizumab-rzaa) now available in the U.S. as a single 150 mg injection for adults with moderate to severe plaque psoriasis. News release. AbbVie. Accessed August 9, 2021. https://www.prnewswire.com/news-releases/skyrizi-risankizumab-rzaa-now-available-in-the-us-as-a-single-150-mg-injection-for-adults-with-moderate-to-severe-plaque-psoriasis-301350489.html
  2. Skyrizi [package insert]. North Chicago, IL: AbbVie, Inc; 2021.